京新药业(002020) - 2014 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2014 was ¥272,928,143.87, representing a 25.87% increase compared to ¥216,841,219.50 in the same period last year[9] - Net profit attributable to shareholders was ¥24,687,096.21, a significant increase of 78.1% from ¥13,861,458.86 year-on-year[9] - The total profit for the period was ¥28,738,239.86, reflecting a 77.38% increase from ¥16,201,066.54 in the previous year[17] - Operating profit increased by CNY 14.56 million, a year-on-year growth of 100.09%, primarily due to increased sales revenue of finished drugs[20] - Total profit increased by CNY 12.54 million, a year-on-year growth of 77.38%, mainly driven by the increase in operating profit[20] - Net profit increased by CNY 10.83 million, a year-on-year growth of 78.10%, primarily due to the increase in operating profit[20] - The company expects net profit attributable to shareholders for the first half of 2014 to range from CNY 51.00 million to CNY 61.50 million, representing a growth of 50% to 80% compared to CNY 33.97 million in the same period of 2013[23] Cash Flow and Assets - The net cash flow from operating activities surged to ¥75,668,082.70, marking a 558.36% increase from ¥11,493,370.42 in the previous year[9] - Total assets at the end of the reporting period were ¥1,383,484,537.29, up 4.44% from ¥1,324,630,819.08 at the end of the previous year[9] - The company's net assets attributable to shareholders increased to ¥842,665,120.76, a 3.02% rise from ¥817,978,024.55 at the end of the last year[9] - The weighted average return on net assets improved to 2.97%, up from 1.78% in the previous year[9] Shareholder Information - The company had a total of 15,380 shareholders at the end of the reporting period[12] Receivables and Prepayments - The company reported a significant increase in prepayments, which rose by 78.61% to ¥20,552,696.77, primarily due to increased payments for equipment and materials[17] - Other receivables increased by CNY 4.53 million, a growth of 57.58%, mainly due to increased technical development and personal loans[18] - Advance receipts increased by CNY 4.96 million, a growth of 44.79%, primarily due to an increase in advance payments[18] Expenses - Sales expenses increased by CNY 18.91 million, a year-on-year growth of 47.90%, mainly due to increased sales revenue and promotional expenses[18]